68Ga–Prostate-Specific Membrane Antigen: A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma
نویسندگان
1 Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon
2 Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon
3 Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon
4 Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon
5 Department of Internal Medicine, Hematology/Oncology Division, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon
6 Department of Clinical Diagnostic Radiology, American University of Beirut Medical Center, Riad El Solh, Beirut, Lebanon
doi
10.22038/aojnmb.2020.46939.1314چکیده
68Ga Prostate-specific membrane antigen (PSMA) is an increasingly popular radiopharmaceutical tracer in prostate cancer and is becoming increasingly researched in other cancers such as breast cancer, renal cell carcinoma, glioblastoma multiforme, among others. Cholangiocarcinoma is the second most common primary hepatic malignant tumor; it is an aggressive tumor with a 5-year survival rate of less than 5 %. We herein report a case of primary cholangiocarcinoma detected on 68Ga-PSMA PET-CT conducted as part of follow up for prostate cancer and confirmed by biopsy and immunohistochemistry.
